Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres
| dc.contributor.author | Tassie, J M | |
| dc.contributor.author | Szumilin, E | |
| dc.contributor.author | Calmy, A | |
| dc.contributor.author | Goemaere, E | |
| dc.date.accessioned | 2008-10-24T08:21:36Z | |
| dc.date.available | 2008-10-24T08:21:36Z | |
| dc.date.issued | 2003-09 | |
| dc.identifier.citation | Highly active antiretroviral therapy in resource poor settings: the experience of Medecins Sans Frontieres, 2003, 17 (13):1995-7 AIDS | en |
| dc.identifier.issn | 0269-9370 | |
| dc.identifier.pmid | 12960832 | |
| dc.identifier.doi | 10.1097/01.aids.0000076325.42412.a1 | |
| dc.identifier.uri | http://hdl.handle.net/10144/39594 | |
| dc.description | To access this Research Letter, scroll down to page 1995 in the attachment. | en |
| dc.description.abstract | We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical, immunological and virological responses were analysed. At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to AIDS (London, England) | en |
| dc.subject.mesh | HIV | en |
| dc.subject.mesh | Resource-poor settings | en |
| dc.title | Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres | en |
| dc.contributor.department | Medecins Sans Fronteres | en |
| dc.identifier.journal | AIDS (London, England) | en |
| refterms.dateFOA | 2019-03-04T12:07:53Z | |
| html.description.abstract | We describe the short-term results of highly active antiretroviral therapy (HAART) in seven projects in low and middle income countries. A total of 743 adults were included, and clinical, immunological and virological responses were analysed. At 6 months, outcomes were similar to those observed in western countries, and the probability of remaining on treatment was 94%. The challenge now is to extend access to HAART to the millions in urgent need. |
